Literature DB >> 29988294

Successful stereotactic body radiation therapy for stage I non-small cell lung cancer with malignant hypercalcemia - Case report.

Thinh Chau1, Allan Y Chen1,2.   

Abstract

In patients with lung malignancy, the development of malignant hypercalcemia (MH) carries a dismal prognosis and represents a major therapeutic challenge given that conventional medical treatments have limited durability. Robust and lasting hypercalcemic reversal and symptomatic relief have been documented following surgical tumor resection. Stereotactic body radiation therapy (SBRT) has emerged as an effective treatment modality in medically inoperable patients with Stage I non-small cell lung cancer (NSCLC). In the current report, SBRT achieved durable tumor control and calcemic correction in a medically inoperable 79 year-old man with Stage I NSCLC patient with parathyroid hormone-related peptide (PTHrP)-induced MH.

Entities:  

Keywords:  Malignant hypercalcemia; Stage I non-small cell lung cancer; parathyroid hormone-related peptide; stereotactic body radiation therapy

Year:  2018        PMID: 29988294      PMCID: PMC6018039     

Source DB:  PubMed          Journal:  J Radiosurg SBRT


  13 in total

Review 1.  Clinical practice. Hypercalcemia associated with cancer.

Authors:  Andrew F Stewart
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

2.  Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients.

Authors:  S H Ralston; S J Gallacher; U Patel; J Campbell; I T Boyle
Journal:  Ann Intern Med       Date:  1990-04-01       Impact factor: 25.391

Review 3.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

4.  [Parathyroid Hormone-related Peptide (PTHrP) Producing Lung Cancer Presenting Hypercalcemia; Report of a Case].

Authors:  Takehiko Okagawa; Yoshinori Hiramatsu
Journal:  Kyobu Geka       Date:  2015-03

5.  [Refractory hypercalcemia in patient with lung cancer].

Authors:  Anna Grzywacz; Mirosław Dziuk; Stanisław Niemczyk
Journal:  Pol Merkur Lekarski       Date:  2014-04

Review 6.  Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients.

Authors:  Guy C Jones; Jason D Kehrer; Jenna Kahn; Bobby N Koneru; Ram Narayan; Tarita O Thomas; Kevin Camphausen; Minesh P Mehta; Aradhana Kaushal
Journal:  Clin Lung Cancer       Date:  2015-04-23       Impact factor: 4.785

7.  PTHrP-mediated hypercalcemia: causes and survival in 138 patients.

Authors:  Peter J Donovan; Naomi Achong; Katherine Griffin; John Galligan; Carel J Pretorius; Donald S A McLeod
Journal:  J Clin Endocrinol Metab       Date:  2015-02-26       Impact factor: 5.958

8.  Hypercalcemia induced by parathyroid hormone-related protein from lung cancer tissue.

Authors:  H Tanaka; S Kobayashi; A Masaoka; S Honda; K Yamaguchi
Journal:  Chest       Date:  1991-11       Impact factor: 9.410

Review 9.  Clinical review 51: Management of hypercalcemia.

Authors:  J P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

10.  Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis.

Authors:  Ronica H Nanda; Yuan Liu; Theresa W Gillespie; John L Mikell; Suresh S Ramalingam; Felix G Fernandez; Walter J Curran; Joseph Lipscomb; Kristin A Higgins
Journal:  Cancer       Date:  2015-09-08       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.